Press Releases in 2019

Expanding research tools for Spatial Genomics by combining molecular information with spatial context in one simple assay.

MINNEAPOLIS, July 9, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its President and CEO, Chuck Kummeth, was recently honored with the EY Entrepreneur Of The Year® 2019 Award in the Heartland. The EY awards program recognizes entrepreneurs and leaders of high-growth companies who are excelling in areas such as innovation, financial performance, and personal commitment to their businesses and communities, while also transforming the world. Mr.

MINNEAPOLIS, June 26, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) was recently honored with the "Decade of Contribution Award" at the 2019 (10th) International Conference on Cell Therapy conference. This award recognized the commitment of Bio-Techne's team in China to providing comprehensive support and reliable products and services for the Chinese Biotechnology industry.

MINNEAPOLIS, June 25, 2019 /PRNewswire/ -- Bio-Techne Corporation today announced the appointment of Dr. Rupert Vessey to the company's Board of Directors as an independent director.  Dr. Vessey's appointment brings the total number of Bio-Techne Board members to nine.

MINNEAPOLIS, June 17, 2019 /PRNewswire/ -- Bio-Techne today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its ExoDx Prostate IntelliScore (EPI) test, making it the first exosome-based liquid biopsy test to receive a Breakthrough Device Designation. This designation not only validates the clinical importance of Bio-Techne's EPI test, it also marks a milestone in the advancement of the company's patented technology platform.

MINNEAPOLIS, June 13, 2019 /PRNewswire/ -- Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate IntelliScore (EPI) test in New York, providing a valuable tool to help Urologists rule out unnecessary prostate biopsies.

MINNEAPOLIS, June 4, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced today it has reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc. The transaction has been completed and is being financed through available cash on hand.

MINNEAPOLIS, May 28, 2019 /PRNewswire/ -- Bio-Techne today announced the publication of a recent validation study demonstrating that the proprietary exosome-based liquid biopsy tests from Bio-Techne's Exosome Diagnostics brand may be used to assess the mutational status of the Epidermal Growth Factor Receptor (EGFR) gene in patients with non-small cell lung cancer (NSCLC). The data from this study will be available to discuss at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4 in Chicago, IL.

SHANGHAI and MINNEAPOLIS, April 22, 2019 /PRNewswire/ -- Elpiscience BioPharma and Bio-Techne Corporation announced today that the companies have entered into a strategic collaboration for the development of anti-cancer therapeutics. Under the terms of the agreement, Elpiscience will have access to multiple antibodies from Bio-Techne's extensive product portfolio for use in the development of preclinical, clinical, and commercial biopharmaceuticals.

- Integrated Workflow Combines NanoString's GeoMx DSP High-Plex RNA Assays and Bio-Techne's Highly Sensitive RNAscope Imaging Reagent Portfolio -